RCM
EPZM

Rotella Capital Management’s Epizyme, Inc EPZM Stock Holding History

Rotella Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-21,900
Closed -$411K – 609
2015
Q1 		$411K Buy
+21,900
New +$452K 0.34% 58

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Rotella Capital Management's EPZM Position: Q2 2015 in Review

Rotella Capital Management sold out of Epizyme, Inc (EPZM) in Q2 2015, closing a stake of 21,900 shares — an estimated $411K sold.

Rotella Capital Management first reported a position in EPZM in Q1 2015 and held it in 1 quarter. The position peaked at $411K in Q1 2015. 95 funds tracked by Wall St. Rank hold EPZM as of Q2 2015.

  • Rotella Capital Management reported no remaining Epizyme, Inc position as of Q2 2015 after selling out during the quarter.
  • Rotella Capital Management sold 21,900 Epizyme, Inc shares in Q2 2015, an estimated $411K.
  • Rotella Capital Management first reported a position in Epizyme, Inc in Q1 2015 and held it in 1 quarter.
  • Rotella Capital Management's Epizyme, Inc position peaked at $411K in Q1 2015.
  • 95 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2015.

Based on Rotella Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.